This wiki has undergone a migration to Confluence found Here
Difference between revisions of "Abbreviated New Drug Application"
Jump to navigation
Jump to search
(New page: Generic drug applications are called "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. ...) |
|||
| Line 1: | Line 1: | ||
Generic drug applications are called "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, a generic applicant must scientifically demonstrate that its product is bioequivalent (i.e., performs in the same manner as the innovator drug). Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public. | Generic drug applications are called "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, a generic applicant must scientifically demonstrate that its product is bioequivalent (i.e., performs in the same manner as the innovator drug). Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public. | ||
| + | ==Additional Regional Definitions and Synonyms== | ||
| + | ''None'' | ||
| + | |||
| + | ==External Links== | ||
| + | [http://www.fda.gov/Cder/drugsatfda/glossary.htm#A Drugs@FDA Glossary of Terms ] | ||
| + | [[Category:RPS Glossary]] | ||
Latest revision as of 18:02, 29 September 2008
Generic drug applications are called "abbreviated" because they are generally not required to include preclinical (animal) and clinical (human) data to establish safety and effectiveness. Instead, a generic applicant must scientifically demonstrate that its product is bioequivalent (i.e., performs in the same manner as the innovator drug). Once approved, an applicant may manufacture and market the generic drug product to provide a safe, effective, low cost alternative to the American public.
Additional Regional Definitions and Synonyms
None
